The Difference between Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate and All-Cause and Cardiovascular Mortality in Populations with Cardiovascular-Kidney-Metabolic Syndrome Stages 0–3: A Prospective Cohort Study
American Journal of Nephrology · 2025
DOI: 10.1159/000548582 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift American Journal of Nephrology, 2025. Verfasst von Xunliang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Glomerular Filtration Rate, Cystatin C, Metabolic Syndrome, Cardiovascular Diseases. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
Introduction
Cardiovascular-kidney-metabolic (CKM) syndrome represents an integrated pathophysiological framework encompassing cardiovascular disease, kidney dysfunction, and metabolic disorders. The difference between cystatin C-based and creatinine-based estimated glomerular filtration rate (eGFRdiff) may reflect pathophysiological processes beyond kidney function, yet its prognostic significance across CKM syndrome stages remains poorly understood.
Methods
We examined records from 4,382 adult participants diagnosed with CKM syndrome (stages 0–3) extracted from the National Health and Nutrition Examination Survey database (1999–2004), with mortality surveillance continuing through December 2019. eGFRdiff was calculated using both absolute difference (eGFRabdiff) and the ratio (eGFRrediff) between cystatin C- and creatinine-based calculations. To investigate associations with overall and cardiovascular mortality outcomes, we employed Cox proportional hazard regression models with adjustments for demographic factors, clinical parameters, and biochemical indicators.
Results
Throughout a median surveillance period spanning 201.8 months, we documented 1,034 fatalities (15.69% of the cohort), with cardiovascular events accounting for 230 deaths (22.2% of all deaths, representing 3.24% of the entire cohort). After comprehensive adjustment in our statistical models, participants exhibiting a negative absolute eGFRdiff (eGFRabdiff
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
- Institute of Kidney Disease, Inflammation and Immunity Mediated Diseases, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.
- Department of Nephrology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China, wangdeguang@ahmu.edu.cn.
- Institute of Kidney Disease, Inflammation and Immunity Mediated Diseases, The Second Affiliated Hospital of Anhui Medical University, Hefei, China, wangdeguang@ahmu.edu.cn.
Zitieren
APA
Li, X., Zhao, L., Zhao, W., Sun, T., Pan, H., & Wang, D. (2025). The Difference between Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate and All-Cause and Cardiovascular Mortality in Populations with Cardiovascular-Kidney-Metabolic Syndrome Stages 0–3: A Prospective Cohort Study. American Journal of Nephrology. https://doi.org/10.1159/000548582
Vancouver
Li X, Zhao L, Zhao W, Sun T, Pan H, Wang D. The Difference between Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate and All-Cause and Cardiovascular Mortality in Populations with Cardiovascular-Kidney-Metabolic Syndrome Stages 0–3: A Prospective Cohort Study. American Journal of Nephrology. 2025. doi:10.1159/000548582
BibTeX
@article{Li2025,
author = {Li, Xunliang and Zhao, Li and Zhao, Wenman and Sun, Tongxin and Pan, Haifeng and Wang, Deguang},
title = {The Difference between Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate and All-Cause and Cardiovascular Mortality in Populations with Cardiovascular-Kidney-Metabolic Syndrome Stages 0–3: A Prospective Cohort Study},
journal = {American Journal of Nephrology},
year = {2025},
doi = {10.1159/000548582}
}
EUVIMED